Editas Medicine (EDIT) Total Debt (2024 - 2025)
Editas Medicine (EDIT) reported Total Debt of $58.6 million for Q4 2025, up 2.04% year-over-year from $57.4 million in Q4 2024, and down 0.79% on a QoQ basis from $59.1 million in Q3 2025.
Editas Medicine (EDIT) has 2 years of Total Debt data on file, last reported at $58.6 million in Q4 2025.
- Quarterly Total Debt rose 2.04% year-over-year to $58.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $58.6 million (up 2.04% YoY) and the FY2025 annual result came in at $58.6 million, up 2.04% from the prior year.
- Total Debt declined to $58.6 million in Q4 2025 per EDIT's latest filing, from $59.1 million in the prior quarter.
- Across five years, Total Debt topped out at $59.1 million in Q3 2025 and bottomed at $54.6 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | 58.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 58.61 Mn |
| Sep 30, 2025 | 59.07 Mn |
| Jun 30, 2025 | 56.67 Mn |
| Mar 31, 2025 | 54.58 Mn |
| Dec 31, 2024 | 57.43 Mn |